Vinay Mathew Thomas
( out of 13 reviews )

Vinay Mathew Thomas, MBBS

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

4K, Hematology Inpatient
Salt Lake City
801-646-9500
Directions

  • Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)

    Patient Rating

    5.0 /5
    ( out of 13 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    January 25, 2025
    HUNTSMAN CANCER CENTER

    Dr. Thomas is incredible. Nicest, most caring and outgoing doctor I have ever seen. He is exceptional at what he does!!!

    December 21, 2024
    HUNTSMAN CANCER CENTER

    I look forward to seeing him next year!

    December 14, 2024
    HUNTSMAN CANCER CENTER

    Doctor Thomas is my favorite doctor of all time! He treats me with respect and he is easy to talk to about my treatments! So happy to have been blessed with him being my doctor!!

    December 11, 2024
    HUNTSMAN CANCER CENTER

    Very helpful, you can tell he cares!

    November 24, 2024
    HUNTSMAN CANCER CENTER

    Have strong faith that he is sincerely committed to my successful treatments.

  • Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)

    Education history

    Fellowship Hematology/Oncology - Huntsman Cancer Institute, University of Utah Spencer Fox Eccles School of Medicine Fellow
    Chief Resident Internal Medicine - University of Connecticut School of Medicine Chief Medical Resident
    Residency Internal Medicine - University of Connecticut School of Medicine Resident
    Professional Medical Medicine - Thiruvananthapuram Medical College M.B.B.S.

    Selected Publications

    Journal Article

    1. Gebrael G, Sahu KK, Chigarira B, Tripathi N, Mathew Thomas V, Sayegh N, Maughan BL, Agarwal N, Swami U, Li H (2023). Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0. Cancers (Basel), 15(14). (Read full article)
    2. Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U (2022). Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. Eur Urol Focus, 9(1), 106-109. (Read full article)
    3. McFarland TR, Mathew Thomas V, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U (2022). Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. Biomedicines, 10(12). (Read full article)
    4. Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N (2022). SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res, 28(22), 4917-4925. (Read full article)
    5. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol, 40(11), 493.e1-493.e7. (Read full article)
    6. Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583. (Read full article)
    7. Mathew Thomas V, Gilreath JA, Newton S, Smock KJ, Lim MY (2021). Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. Haemophilia, 27(4), e563-e566. (Read full article)
    8. Singh M, Thomas VM, Mulay S (2020). Bortezomib-induced motor neuropathy: A case report. J Oncol Pharm Pract, 26(6), 1549-1552. (Read full article)
    9. Chango Azanza JJ, Calle Sarmiento PM, Mathew Thomas V, Lopetegui Lia N, Kidwai N (2020). Tumor Lysis Syndrome Caused by Unrecognized Richter's Transformation of Chronic Lymphocytic Leukemia: Treatment With Venetoclax for Suspected Disease Progression. Cureus, 12(5), e8145. (Read full article)
    10. Mathew Thomas V, Alexander SA, Hadfield MJ, Vredenburgh J (2020). A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure. Cureus, 12(4), e7796. (Read full article)
    11. Alexander SA, Mathew Thomas V, Savage JA (2020). Elevated C-reactive Protein and Role of Steroids in Cocaine-associated Levamisole-induced Vasculitis. Cureus, 12(4), e7597. (Read full article)
    12. Chango Azanza JJ, Mathew Thomas V, Calle Sarmiento PM, Singh M, Alexander SA (2020). Spontaneous Tumor Lysis Syndrome Due to Endometrial Carcinoma. Cureus, 12(3), e7220. (Read full article)
    13. Mathew Thomas V, Bindal P, Ann Alexander S, McDonald K (2019). Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. J Oncol Pharm Pract, 26(2), 459-461. (Read full article)
    14. Mathew Thomas V, Alexander SA, Bindal P, Vredenburgh J (2020). Idiopathic Granulomatous Mastitis-A Mystery Yet to be Unraveled: A Case Series and Review of Literature. Cureus, 12(2), e6895. (Read full article)
    15. Mathew Thomas V, Bindal P, Vredenburgh JJ (2019). Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma. Case Rep Oncol, 12(1), 126-130. (Read full article)
    16. Thomas VM, Thomas-Eapen N (2017). An Uncommon Side Effect of a Commonly Used Antibiotic: Amoxicillin-Clavulanic Acid Induced Hepatitis. Korean J Fam Med, 38(5), 307-310. (Read full article)

    Review

    1. Mathew Thomas V, Tripathi N, Agarwal N, Swami U (2022). Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. [Review]. Expert Rev Anticancer Ther, 22(4), 335-341. (Read full article)
    2. Thomas VM, Abou-Ismail MY, Lim MY (2021). Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature. [Review]. Haemophilia, 28(1), 4-17. (Read full article)

    Editorial

    1. Gebrael G, Thomas VM, Swami U, Agarwal N (2022). The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice. Oncologist, 28(9), 746-749. (Read full article)

    Letter

    1. Thomas VM, Mathew A (2020). Brain Share, Not Brain Drain. [Letter to the editor]. JCO Glob Oncol, 6, 504. (Read full article)